The laboratory of Stephanie Humblet-Baron applies an advanced, high-throughput immunophenotyping platform for in-depth immune profiling to systems analyses and clinical studies.
Since 2109, her group is running several clinical studies investigating the immune landscape using systems immunology with the aim of unravelling underlying immune mechanisms involved in the studied disorders including Inborn errors of immunity, infectious diseases, cancer and neurological diseases (MS, Alzheimer’s disease).
Applicants should hold a Master degree (or equivalent) in biology, health sciences or a related discipline, Doctor in Medicine is a strong advantage
Motivation to perform top clinical immunology and mechanistic disease research
Motivation to build a research career
Strong academic record (in the top 20% of your group)
Bioinformatics experience is a plus.
Enjoy working in a team and communicating.
Skills in flow cytometry is an advantage.
CAR T-cell therapy has recently emerged as a novel important therapeutic tool in patients with advanced B cell malignancies.
This treatment is targeting specifically the CD19 expression on B lymphocytes and has shown remarkable efficacy even in patients with relapsed / refractory disease.
While showing promising results, there is to date, very little known on the immune mechanism supporting long-term response.
Using new systems-level technologies (including advanced flow cytometry and single-cell RNA sequencing) we aim at exploring in-depth the immune landscape of patients receiving CAR T-cell therapy.
Applying a machine learning approach, we intend to determine the immunological basis of CAR T-cell persistence. This mechanistic understanding into immune responses has the potential to be later translated into prognosis prediction of which individuals will show efficacious responses and which are more likely to relapse.